A selective cannabinoid-1 receptor antagonist, PF-95453, reduces body weight and body fat to a greater extent than pair-fed controls in obese monkeys

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 1, 2010, Pages 103-113

  Wagner, Janice D ^a   Zhang, Li ^a   Kavanagh, Kylie ^a   Ward, Gina M ^a   Chin, Janice E ^b   Hadcock, John R ^b   Auerbach, Bruce J ^b   Harwood Jr , H James ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [7 (2 CHLOROPHENYL) 8 (4 CHLOROPHENYL) 2 METHYLPYRAZOLO[1,5 A][1,3,5]TRIAZIN 4 YL] 3 (METHYLAMINO)AZETIDINE 3 CARBOXAMIDE; ADIPONECTIN; AZETIDINE DERIVATIVE; CANNABINOID 1 RECEPTOR ANTAGONIST; LEPTIN; PF 95453; UNCLASSIFIED DRUG; 1-(7-(2-CHLOROPHENYL)-8-(4-CHLOROPHENYL)-2-METHYLPYRAZOLO(1,5-A)(1,3,5)TRIAZIN-4-YL)-3-(METHYLAMINO)AZETIDINE-3-CARBOXAMIDE; ANTIOBESITY AGENT; CANNABINOID 1 RECEPTOR; GLUCOSE BLOOD LEVEL; LIPID; TRIAZINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY FAT; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; HUMAN; HUMAN CELL; MACACA; MALE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOASSAY; BLOOD; BODY COMPOSITION; BODY WEIGHT; DIET; DOG; DOSE RESPONSE; DRUG EFFECTS; EATING; FEEDING BEHAVIOR; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; MACACA FASCICULARIS; METABOLISM; PHYSIOLOGY; RAT; SPRAGUE DAWLEY RAT;

ADIPONECTIN; ADIPOSITY; ANIMALS; ANTI-OBESITY AGENTS; AZETIDINES; BLOOD GLUCOSE; BODY COMPOSITION; BODY WEIGHT; DIET; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; ENDPOINT DETERMINATION; FEEDING BEHAVIOR; GLUCOSE TOLERANCE TEST; LEPTIN; LIPIDS; MACACA FASCICULARIS; MALE; OBESITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, CANNABINOID, CB1; TRIAZINES; WEIGHT LOSS;

EID: 77957237048     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.168187     Document Type: Article

References (40)

1. Akbas F, Gasteyger C, Sjödin A, Astrup A, and Larsen TM (2009) A critical review of the cannabinoid receptor as a drug target for obesity management. Obes Rev 10:58-67.
2. Arnold JC, Topple AN, Mallet PE, Hunt GE, and McGregor IS (2001) The distribution of cannabinoid-induced Fos expression in rat brain: differences between the Lewis and Wistar strain. Brain Res 921:240-255.
3. Arnone M, Maruani J, Chaperon F, Thiébot MH, Poncelet M, Soubrié P, and Le Fur G (1997) Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 132:104-106. (Pubitemid 27303746)
4. 1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 63:908-914.
5. Butler H and Korbonits M (2009) Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists. Eur J Endocrinol 161:655-662.
6. Cao X, Liang L, Hadcock JR, Iredale PA, Griffith DA, Menniti FS, Factor S, Greenamyre JT, and Papa SM (2007) Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. J Pharmacol Exp Ther 323:318-326.
7. 1-R) antagonists. Bioorg Med Chem Lett 16:731-736.
8. Cota D, Marsicano G, Tschöp M, Grübler Y, Flachskamm C, Schubert M, Auer D, Yassouridis A, Thöne-Reineke C, Ortmann S, et al. (2003) The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112:423-431.
9. Cota D, Sandoval DA, Olivieri M, Prodi E, D'Alessio DA, Woods SC, Seeley RJ, and Obici S (2009) Food intake-independent effects of CB1 antagonism on glucose and lipid metabolism. Obesity 17:1641-1645.
10. de Kloet AD and Woods SC (2009) Minireview: endocannabinoids and their receptors as targets for obesity therapy. Endocrinology150:2531-2536.
11. De Petrocellis L, Cascio MG, and Di Marzo V (2004) The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141:765-774.
12. Di Marzo V and Matias I (2005) Endocannabinoid control of food intake and energy balance. Nat Neurosci 8:585-589.
13. Dow RL, Carpino PA, Hadcock JR, Black SC, Iredale PA, DaSilva-Jardine P, Schneider SR, Paight ES, Griffith DA, Scott DO, et al. (2009) Discovery of 2-(2-chlorophenyl)-3-(4-chlorophenyl)-7-(2,2-difluoropropyl)-6, 7-dihydro-2H-pyrazolo[3,4-f][1,4]oxazepin-8(5H)-one (PF-514273) a novel, bicyclic lactam-based cannabinoid-1 receptor antagonist for the treatment of obesity. J Med Chem 52:2652-2655.
14. Engeli S, Böhnke J, Feldpausch M, Gorzelniak K, Janke J, Bátkai S, Pacher P, Harvey-White J, Luft FC, Sharma AM, et al. (2005) Activation of the peripheral endocannabinoid system in human obesity. Diabetes 54:2838-2843.
15. Fernandez-Real JM, Lopez-Bermejo A, Casamitjana R, and Ricart W (2004) Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrin Metab 88:2714-2718. (Pubitemid 36724447)
16. Galiègue S, Mary S, Marchand J, Dussossoy D, Carrière D, Carayon P, Bouaboula M, Shire D, Le Fur G, and Casellas P (1995) Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem 232:54-61.
17. 1 receptor antagonist. J Med Chem 52:234-237.
18. Hao S, Avraham Y, Mechoulam R, and Berry EM (2000) Low dose anandamide affects food intake, cognitive function, neurotransmitter and corticosterone levels in diet-restricted mice. Eur J Pharmacol 392:147-156. (Pubitemid 30184903)
19. Harwood HJ Jr, Petras SF, Shelly LD, Zaccaro LM, Perry DA, Makowski MR, Hargrove DM, Martin KA, Tracey WR, Chapman JG, et al. (2003) Isozyme-nonselective N-substituted bipiperidylcarboxamide acetyl-CoA carboxylase inhibitors reduce tissue malonyl-CoA concentrations, inhibit fatty acid synthesis, and increase fatty acid oxidation in cultured cells and in experimental animals. J Biol Chem 278:37099-37111.
20. Herkenham M, Lynn AB, Johnson MR, Melvin LS, de Costa BR, and Rice KC (1991) Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11:563-583.
21. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54:161-202.
22. 1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19:1567-1569.
23. Kunos G, Osei-Hyiaman D, Liu J, Godlewski G, and Bátkai S (2008) Endocannabinoids and the control of energy homeostasis. J Biol Chem 283:33021-33025.
24. Lin LS, Lanza TJ Jr, Jewell JP, Liu P, Shah SK, Qi H, Tong X, Wang J, Xu SS, Fong TM, et al. (2006) Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3- cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy} propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem 49:7584-7587.
25. LoVerme J, Duranti A, Tontini A, Spadoni G, Mor M, Rivara S, Stella N, Xu C, Tarzia G, and Piomelli D (2009) Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett 19:639-643.
26. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, Petrosino S, Hoareau L, Festy F, Pasquali R, et al. (2006) Regulation, function, and dysregulation of endocannabinoids in models of adipose and β-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91:3171-3180.
27. Maurer TS, Debartolo DB, Tess DA, and Scott DO (2005) Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice. Drug Metab Dispos 33:175-181.
28. McElroy J, Sieracki C, and Chorvat R (2008) Non-brain penetrant CB1 receptor antagonists as novel treatment of obesity and related metabolic disorders. Obesity 16 (Suppl. 1):S47.
29. Morton GJ, Cummings DE, Baskin DG, Barsh GS, and Schwartz MW (2006) Central nervous system control of food intake and body weight. Nature 443:289-295.
30. Nogueiras R, Diaz-Arteaga A, Lockie SH, Velásquez DA, Tschop J, López M, Cadwell CC, Diéguez C, and Tschöp MH (2009) The endocannabinoid system: role in glucose and energy metabolism. Pharmacol Res 60:93-98.
31. Nogueiras R, Veyrat-Durebex C, Suchanek PM, Klein M, Tschöp J, Caldwell C, Woods SC, Wittmann G, Watanabe M, Liposits Z, et al. (2008) Peripheral, but not central, CB1 antagonism provides food intake independent metabolic benefits in diet-induced obese rats. Diabetes 57:2977-2991.
32. Osei-Hyiaman D, Liu J, Zhou L, Godlewski G, Harvey-White J, Jeong WI, Bátkai S, Marsicano G, Lutz B, Buettner C, et al. (2008) Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 118:3160-3169.
33. Pagotto U, Marsicano G, Cota D, Lutz B, and Pasquali R (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27:73-100.
34. Poirier B, Bidouard JP, Cadrouvele C, Marniquet X, Staels B, O'Connor SE, Janiak P, and Herbert JM (2005) The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 7:65-72.
35. Quarta C, Bellocchio L, Mancini G, Mazza R, Cervino C, Braulke LJ, Fekete C, Latorre R, Nanni C, Bucci M, et al. (2010) CB1 signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab 11:273-285.
36. Rinaldi-Carmona M, Barth F, Héaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Néliat G, and Caput D (1994) SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 350:240-244.
37. Tan KC, Xu A, Chow WS, Lam MC, Ai VH, Tam SC, and Lam KS (2004) Hypoadiponectinemia is associated with impaired endothelium-dependent vasodilation. J Clin Endocrinol Metab 89:765-769. (Pubitemid 38269891)
38. Wagner JD, Kavanagh K, Ward GM, Auerbach BJ, Harwood HJ Jr, and Kaplan JR (2006) Old world nonhuman primate models of type 2 diabetes mellitus. ILAR J 47:259-271. (Pubitemid 43986034)
39. Wagner JD, Shadoan MK, Zhang L, Ward GM, Royer LJ, Kavanagh K, Francone OL, Auerbach BJ, and Harwood HJ Jr (2010) A selective peroxisome proliferator-activated receptor α agonist, CP-900691, improves plasma lipids, lipoproteins, and glycemic control in diabetic monkeys. J Pharmacol Exp Ther 333:844-853.
40. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, and Chuang LM (2001) Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 86:3815-3819. (Pubitemid 32755982)